Michael Auer

Dr. Michael Auer


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2020 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
SHSigne Hässler
Signe Hässler
DBDelphine Bachelet
Delphine Bachelet
JDJulianne Duhaze
Julianne Duhaze
NSNatacha Szely
Natacha Szely
AGAude Gleizes
Aude Gleizes
ACABIRISK consortium
ABIRISK consortium
Biopharmaceutical products (BPs) are widely used to treat autoimmune diseases, but immunogenicity limits their efficacy for an important proportion of patients. Our knowledge of patient-related factors influencing the occurrence of antidrug antibodies (ADAs) is still limited. The European consortium ABIRISK (Anti-Biopharmaceutical Immunization: prediction and analysis of clinical relevance to minimize the RISK) conducted a clinical and genomic multicohort prospective study of 560 patients with multiple sclerosis (MS, n = 147), rheumatoid arthritis (RA, n = 229), Crohn’s disease (n = 148), or ulcerative colitis (n = 36) treated with 8 different biopharmaceuticals (etanercept, n = 84; infliximab, n = 101; adalimumab, n = 153; interferon [IFN]-beta-1a intramuscularly [IM], n = 38; IFN-beta-1a subcutaneously [SC], n = 68; IFN-beta-1b SC, n = 41; rituximab, n = 31; tocilizumab, n = 44) and followed during the first 12 months of therapy for time to ADA development. From the bioclinical data collected, we explored the relationships between patient-related factors and the occurrence of ADAs. Both baseline and time-dependent factors such as concomitant medications were analyzed using Cox proportional hazard regression models. Mean age and disease duration were 35.1 and 0.85 years, respectively, for MS; 54.2 and 3.17 years for RA; and 36.9 and 3.69 years for inflammatory bowel diseases (IBDs). In a multivariate Cox regression model including each of the clinical and genetic factors mentioned hereafter, among the clinical factors, immunosuppressants (adjusted hazard ratio [aHR] = 0.408 [95% confidence interval (CI) 0.253–0.657], p < 0.001) and antibiotics (aHR = 0.121 [0.0437–0.333], p < 0.0001) were independently negatively associated with time to ADA development, whereas infections during the study (aHR = 2.757 [1.616–4.704], p < 0.001) and tobacco smoking (aHR = 2.150 [1.319–3.503], p < 0.01) were positively associated. 351,824 Single-Nucleotide Polymorphisms (SNPs) and 38 imputed Human Leukocyte Antigen (HLA) alleles were analyzed through a genome-wide association study. We found that the HLA-DQA1*05 allele significantly increased the rate of immunogenicity (aHR = 3.9 [1.923–5.976], p < 0.0001 for the homozygotes). Among the 6 genetic variants selected at a 20% false discovery rate (FDR) threshold, the minor allele of rs10508884, which is situated in an intron of the CXCL12 gene, increased the rate of immunogenicity (aHR = 3.804 [2.139–6.764], p < 1 × 10−5 for patients homozygous for the minor allele) and was chosen for validation through a CXCL12 protein enzyme-linked immunosorbent assay (ELISA) on patient serum at baseline before therapy start. CXCL12 protein levels were higher for patients homozygous for the minor allele carrying higher ADA risk (mean: 2,693 pg/ml) than for the other genotypes (mean: 2,317 pg/ml; p = 0.014), and patients with CXCL12 levels above the median in serum were more prone to develop ADAs (aHR = 2.329 [1.106–4.90], p = 0.026). A limitation of the study is the lack of replication; therefore, other studies are required to confirm our findings. In our study, we found that immunosuppressants and antibiotics were associated with decreased risk of ADA development, whereas tobacco smoking and infections during the study were associated with increased risk. We found that the HLA-DQA1*05 allele was associated with an increased rate of immunogenicity. Moreover, our results suggest a relationship between CXCL12 production and ADA development independent of the disease, which is consistent with its known function in affinity maturation of antibodies and plasma cell survival. Our findings may help physicians in the management of patients receiving biotherapies.

1 April 2018 in Journal of Women's Health
Verified
Journal Article
Closed access
MAMichael Auer
Michael Auer
BFBirgit Frauscher
Birgit Frauscher
MHMargarethe Hochleitner
Margarethe Hochleitner
BHBirgit Högl
Birgit Högl
Background: Previous studies have shown that women have less access or longer waiting times to high-tech medicine compared with men. This study aimed to detect possible gender differences in access to the diagnostic high-tech method of polysomnography (PSG). Furthermore, the study explored gender differences in prevalence of specific sleep diseases. Materials and Methods: Source data of n = 1000 patients, who underwent PSG at the Medical University of Innsbruck, were reviewed. Clinical data regarding time elapsed between symptom onset and PSG as well as final diagnoses were analyzed for gender differences. Results: Six hundred sixty-nine men and 331 women were examined with PSG. There were no gender differences in access to PSG after first presentation to the sleep laboratory. Significantly more men than women (13.3 vs. 6.9%) were referred to medical examination because of abnormal observations by their bed partner. In men we found more sleep-related breathing disorders and fragmentary myoclonus, whereas in women insomnia was more common. Sleep-related breathing disorders showed a more severe manifestation in men, however, there was no difference in treatment with continuous positive airway pressure/biphasic positive airway pressure therapy between male and female patients. Conclusion: Twice as many men than women received a PSG. This is explained by the referral rates to the sleep laboratory. While there are well-established gender differences for some sleep disorders, the fact that twice as many men than women were referred to the sleep laboratory could indicate a lower awareness for sleep disorders in women.

1 August 2020 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
MAMichael Auer
Michael Auer
GBGabriel Bsteh
Gabriel Bsteh
HHHarald Hegen
Harald Hegen
SWSebastian Wurth
Sebastian Wurth
AZAnne Zinganell
Anne Zinganell
FPFranziska Di Pauli
Franziska Di Pauli

2 December 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MAMichael Auer
Michael Auer
AZAnne Zinganell
Anne Zinganell
HHHarald Hegen
Harald Hegen
GBGabriel Bsteh
Gabriel Bsteh
FPFranziska Di Pauli
Franziska Di Pauli
FDFlorian Deisenhammer
Florian Deisenhammer
Natalizumab (NTZ) has been used for treatment of highly active relapsing–remitting multiple sclerosis (MS). When stopping NTZ the risk of severe rebound phenomenon has to be considered. We aimed to investigate the use of NTZ in clinical routine and focused on identification of potential risk factors for disease reactivation after treatment discontinuation. At the Medical University of Innsbruck, Austria, we identified all MS patients who were treated with NTZ and performed a retrospective analysis on therapeutic decision making, disease course before, during and after treatment with NTZ and on risk factors for disease reactivation after NTZ discontinuation. 235 NTZ treated MS patients were included, of whom 105 had discontinued treatment. At NTZ start disease duration was 5.09 (IQR 2.09–10.57) years, average number of total relapses was 4 (IQR 3–6) and median EDSS 2.0 (range 0–6.5), whereby these values significantly decreased over time. Reduction of annualized relapse rate (ARR) on treatment was 93% and EDSS remained stable in 64%. In multivariate regression models only conversion to secondary progressive MS (SPMS) on treatment was significantly associated with lower risk of disease reactivation after NTZ, while ARR before treatment was associated with earlier disease reactivation. We could confirm the high therapeutic efficacy of NTZ which trends to be used earlier in the disease course nowadays. Discontinuation of NTZ seems safe only in patients who convert to SPMS during treatment, while higher ARR before NTZ increases the risk of disease reactivation after treatment discontinuation.

6 June 2019 in Brain and Behavior
Verified
Journal Article
Open access
PDF file
MAMichael Auer
Michael Auer
HHHarald Hegen
Harald Hegen
JSJohann Sellner
Johann Sellner
KOKatrin Oppermann
Katrin Oppermann
GBGabriel Bsteh
Gabriel Bsteh
FDFlorian Deisenhammer
Florian Deisenhammer
Introduction: Determination of antibodies against the John Cunningham virus (JCV) is an important tool for risk stratification in Natalizumab‐treated multiple sclerosis (MS) patients. Six‐monthly testing has been suggested for anti‐JCV antibody negative patients and patients with low antibody index in order to detect changes of serostatus. We conducted a prospective study with predefined testing intervals in order to investigate the predictability of anti‐JCV antibody status and the intervals for repetitive testing.Methods: Our study included 109 patients at the MS Clinic of the Departments of Neurology, Medical Universities of Innsbruck and Salzburg. Blood withdrawals were performed at five time points: baseline, month 1, 3, 6, and 12. Patients’ sera were sent to Unilabs, Copenhagen, Denmark, where anti‐JCV antibodies were tested by a two‐step enzyme‐linked immunosorbent assay. Qualitative (negative/positive) and quantitative results (anti‐JCV antibody index) were used for statistical analyses.Results: In our cohort, 52.3% of the patients were positive for anti‐JCV antibodies at baseline, with a significant correlation with age, but no association with sex or prior disease‐modifying therapy. Seven patients converted and reverted from negative to positive status and vice versa around the cut‐off index of 0.4, but no patient showed a permanent seroconversion from negative to highly positive anti‐JCV antibody status.Conclusion: Long‐term anti‐JCV antibody status, including seroconverters/‐reverters around the cut‐off index, is highly predictable by testing three times within short intervals, however, we cannot suggest clearly defined intervals for repetitive testing. The rate of real seroconverters, i.e., new infections with JCV, per year seems lower than previously described.

28 March 2022 in Journal of Central Nervous System Disease
Verified
Journal Article
Open access
MAMichael Auer
Michael Auer
HHHarald Hegen
Harald Hegen
AHAnna Hotter
Anna Hotter
WLWolfgang Löscher
Wolfgang Löscher
KBKlaus Berek
Klaus Berek
FPFranziska Di Pauli
Franziska Di Pauli
The chimeric anti-CD20 antibody rituximab has demonstrated good efficacy as an off-label treatment in chronic inflammatory demyelinating polyneuropathy (CIDP), while the humanized anti-CD20 antibody ocrelizumab has been approved for treatment of multiple sclerosis (MS), whereas there is no evidence for its use in CIDP so far. We present a patient suffering from CIDP and MS, both refractory to standard treatment and both showing marked improvement on ocrelizumab. To the best of our knowledge, this is a unique report of CIDP with an almost full electrophysiological recovery on ocrelizumab which could be considered as a potential treatment option for refractory CIDP.